vs
Side-by-side financial comparison of Cherry Hill Mortgage Investment Corp (CHMI) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $11.8M, roughly 1.6× Cherry Hill Mortgage Investment Corp). On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -37.2%). Over the past eight quarters, Cherry Hill Mortgage Investment Corp's revenue compounded faster (-15.2% CAGR vs -15.9%).
Cherry Hill Mortgage Investment Corp is a U.S.-headquartered real estate finance firm focused on acquiring, investing in and managing residential mortgage-related assets. Its core holdings include agency mortgage-backed securities, residential loans and mortgage servicing rights, operating primarily in the U.S. domestic housing finance market.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CHMI vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.8M | $18.7M |
| Net Profit | — | $-154.0K |
| Gross Margin | 78.9% | — |
| Operating Margin | 72.1% | -6.9% |
| Net Margin | — | -0.8% |
| Revenue YoY | -37.2% | -25.7% |
| Net Profit YoY | — | 97.6% |
| EPS (diluted) | $0.18 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.8M | — | ||
| Q3 25 | $8.6M | — | ||
| Q2 25 | $6.0M | $18.7M | ||
| Q1 25 | $-3.0M | $50.9M | ||
| Q4 24 | $18.7M | $38.1M | ||
| Q3 24 | $-7.1M | $33.4M | ||
| Q2 24 | $6.6M | $25.1M | ||
| Q1 24 | $16.3M | $41.5M |
| Q4 25 | — | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $1.6M | $-154.0K | ||
| Q1 25 | $-7.0M | $23.5M | ||
| Q4 24 | — | $18.9M | ||
| Q3 24 | $-12.4M | $5.7M | ||
| Q2 24 | $784.0K | $-6.5M | ||
| Q1 24 | $12.1M | $13.8M |
| Q4 25 | 78.9% | — | ||
| Q3 25 | 73.2% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 183.4% | — | ||
| Q4 24 | 83.3% | — | ||
| Q3 24 | 145.3% | — | ||
| Q2 24 | 47.5% | — | ||
| Q1 24 | 83.9% | — |
| Q4 25 | 72.1% | — | ||
| Q3 25 | 56.0% | — | ||
| Q2 25 | 44.4% | -6.9% | ||
| Q1 25 | 223.6% | 44.4% | ||
| Q4 24 | 76.2% | 46.4% | ||
| Q3 24 | 171.8% | 12.3% | ||
| Q2 24 | 22.0% | -33.7% | ||
| Q1 24 | 78.0% | 28.1% |
| Q4 25 | — | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 25.9% | -0.8% | ||
| Q1 25 | 229.2% | 46.2% | ||
| Q4 24 | — | 49.6% | ||
| Q3 24 | 175.8% | 17.2% | ||
| Q2 24 | 11.9% | -26.0% | ||
| Q1 24 | 73.7% | 33.3% |
| Q4 25 | $0.18 | — | ||
| Q3 25 | $0.05 | — | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $-0.29 | — | ||
| Q4 24 | $0.30 | — | ||
| Q3 24 | $-0.49 | — | ||
| Q2 24 | $-0.06 | — | ||
| Q1 24 | $0.32 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.9M | $49.0M |
| Total DebtLower is stronger | $146.3M | — |
| Stockholders' EquityBook value | $236.0M | $119.9M |
| Total Assets | $1.5B | $175.1M |
| Debt / EquityLower = less leverage | 0.62× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.9M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $58.0M | $49.0M | ||
| Q1 25 | $47.3M | $47.6M | ||
| Q4 24 | $46.3M | $38.1M | ||
| Q3 24 | $50.2M | $40.6M | ||
| Q2 24 | $52.4M | $43.2M | ||
| Q1 24 | $47.5M | $36.2M |
| Q4 25 | $146.3M | — | ||
| Q3 25 | $148.0M | — | ||
| Q2 25 | $150.1M | — | ||
| Q1 25 | $150.1M | — | ||
| Q4 24 | $152.1M | — | ||
| Q3 24 | $151.8M | — | ||
| Q2 24 | $160.5M | — | ||
| Q1 24 | $167.5M | — |
| Q4 25 | $236.0M | — | ||
| Q3 25 | $233.1M | — | ||
| Q2 25 | $229.9M | $119.9M | ||
| Q1 25 | $226.6M | $25.0M | ||
| Q4 24 | $230.3M | $-456.0K | ||
| Q3 24 | $236.7M | $-23.5M | ||
| Q2 24 | $234.5M | $-31.2M | ||
| Q1 24 | $247.0M | $-31.7M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $175.1M | ||
| Q1 25 | $1.4B | $98.5M | ||
| Q4 24 | $1.5B | $120.5M | ||
| Q3 24 | $1.6B | $139.0M | ||
| Q2 24 | $1.4B | $159.2M | ||
| Q1 24 | $1.4B | $184.7M |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.1M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.1M | — | ||
| Q3 25 | $-2.4M | — | ||
| Q2 25 | $12.5M | $-15.8M | ||
| Q1 25 | $682.0K | $-21.0M | ||
| Q4 24 | $-4.7M | $-19.9M | ||
| Q3 24 | $4.4M | $-20.7M | ||
| Q2 24 | $4.1M | $-19.5M | ||
| Q1 24 | $-19.1M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | -0.53× | — | ||
| Q2 25 | 7.98× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | 5.18× | — | ||
| Q1 24 | -1.58× | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHMI
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
